Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

BACKGROUND The identification of tumor-associated antigens and the cloning of DNA sequences encoding them have enabled the development of anticancer vaccines. Such vaccines target tumors by stimulating an immune response against the antigens. One method of vaccination involves the delivery of antigen-encoding DNA sequences, and a number of recombinant vectors have been used for this purpose. To optimize the efficacy of recombinant vaccines, we compared primary and booster treatment regimens that used a single vector (i.e., homologous boosting) with regimens that used two different vectors (i.e., heterologous boosting). METHODS Pulmonary tumors (experimental metastases) were induced in BALB/c mice inoculated with CT26.CL25 murine colon carcinoma cells, which express recombinant bacterial beta-galactosidase (the model antigen). Protocols for subsequent vaccination used three vectors that encoded beta-galactosidase--vaccinia (cowpox) virus, fowlpox virus, naked bacterial plasmid DNA. Mouse survival was evaluated in conjunction with antibody and cytotoxic T-lymphocyte responses to beta-galactosidase. RESULTS Heterologous boosting resulted in significantly longer mouse survival than homologous boosting (all P<.0001, two-sided). Potent antigen-specific cytotoxic T lymphocytes were generated following heterologous boosting with poxvirus vectors. This response was not observed with any of the homologous boosting regimens. Mice primed with recombinant poxvirus vectors generated highly specific antibodies against viral proteins. CONCLUSIONS The poor efficacy of homologous boosting regimens with viral vectors was probably a consequence of the induction of a strong antiviral antibody response. Heterologous boosting augmented antitumor immunity by generating a strong antigen-specific cytotoxic T-lymphocyte response. These data suggest that heterologous boosting strategies may be useful in increasing the efficacy of recombinant DNA anticancer vaccines that have now entered clinical trials.

[1]  J. Schlom,et al.  Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. , 1997, Vaccine.

[2]  J. Yewdell,et al.  MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. , 1997, Journal of immunology.

[3]  S. Rosenberg.  Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.

[4]  A. García-Sastre,et al.  Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. , 1996, Cellular immunology.

[5]  B. Moss,et al.  IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. , 1996, Journal of immunology.

[6]  H. Pircher,et al.  On T Cell Memory: Arguments for Antigen Dependence , 1996, Immunological reviews.

[7]  S. Rosenberg,et al.  Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. , 1996, Journal of immunology.

[8]  P. Borrow,et al.  Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection , 1995, Journal of virology.

[9]  P. Coulie,et al.  From defined human tumor antigens to effective immunization? , 1995, Immunology today.

[10]  S. Rosenberg,et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.

[11]  S. Rosenberg,et al.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.

[12]  J. Lippolis,et al.  virus 40 T antigen . cytotoxic T-lymphocyte epitopes within simian Hierarchy among multiple H-2 b-restricted , 1995 .

[13]  D. Fuller,et al.  Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. , 1995, Vaccine.

[14]  H. von Boehmer,et al.  On the cellular basis of immunological T cell memory. , 1995, Immunity.

[15]  D. Fuller,et al.  A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. , 1994, AIDS research and human retroviruses.

[16]  M. Skinner,et al.  Deletion of fowlpox virus homologues of vaccinia virus genes between the 3 beta-hydroxysteroid dehydrogenase (A44L) and DNA ligase (A50R) genes. , 1994, The Journal of general virology.

[17]  J. Schlom,et al.  Immune response to a carcinoembryonic antigen polynucleotide vaccine. , 1994, Cancer research.

[18]  R M Zinkernagel,et al.  Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. , 1993, Journal of immunology.

[19]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[20]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[21]  R. Zinkernagel,et al.  Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. , 1993, Vaccine.

[22]  D. Montefiori,et al.  Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. , 1992, The Journal of infectious diseases.

[23]  J. Schlom,et al.  Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. , 1992, Journal of the National Cancer Institute.

[24]  P. Greenberg,et al.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein , 1991, The Lancet.

[25]  S. Goebel,et al.  Nucleotide sequence analysis of a 10.5 kbp HindIII fragment of fowlpox virus: relatedness to the central portion of the vaccinia virus HindIII D region. , 1990, The Journal of general virology.

[26]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[27]  D. Gray,et al.  T cell memory is short-lived in the absence of antigen , 1988, Nature.

[28]  J. Brown,et al.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.